Lyon recently examined survival outcomes among patients with metastatic renal cell carcinoma (mRCC) treated with or without complete surgical metastasectomy (SM) during an era when targeted therapy and checkpoint inhibitors were available ( ). They reported a greater 2-year cancer-specific survival (CSS) in patients who underwent complete SM than in those who did not (84% 54%, P<0.001) and that complete SM was associated with a significantly reduced likelihood of death from RCC after adjusting for age, sex, and the timing, number, and location of metastases. They concluded that metastasectomy may be considered for appropriately selected patients, even in the post-cytokine era.
展开▼
